<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04882618</url>
  </required_header>
  <id_info>
    <org_study_id>TSA-2019-9393</org_study_id>
    <nct_id>NCT04882618</nct_id>
  </id_info>
  <brief_title>Use of Indocyanine Green During Pelvic Lymph Node Dissection in Prostate Cancer.</brief_title>
  <official_title>Is the Extended Lymph Node Dissection Under Indocyanine Green (ICG) Based Fluorescence Imaging Superior to Conventional Extended Lymph Node Dissection During Laparoscopic Radical Prostatectomy(LRRP)?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TC Erciyes University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TC Erciyes University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Standard treatment of local or locally advanced prostate cancer is radical prostatectomy&#xD;
      (RRP) surgery. During RRP in certain patients extended lymph node dissection (ELND) is&#xD;
      recommended. to detect eligible patients for ELND some nomograms based on clinical factors of&#xD;
      them is used. The Briganti nomogram is one of them. If the patient has 7% or more probability&#xD;
      on Briganti nomogram, then ELND is recommended. But ELND is complicated surgical procedure&#xD;
      and may cause labor lost and cost.&#xD;
&#xD;
      It is aimed here to show whether the ICG based fluorescence imaging during laparoscopy may&#xD;
      yield higher accuracy to detect metastatic LNs than the conventional ELND?&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      50 patients with diagnosis of local or locally advance prostate cancer and having LN invasion&#xD;
      probability between 7-50% on 2018 Briganti Nomogram will be included to this study.&#xD;
&#xD;
      Before Laparoscopic radical prostatectomy (LRRP), ICG is injected left and right lobe of the&#xD;
      propagate during cystoscopy.&#xD;
&#xD;
      Extended LND is performed in all patients. But before it, fluorescence imaging will be done,&#xD;
      and ICG positive lymph nodes (LN) are dissected and sent pathology separately.&#xD;
&#xD;
      Positive LN yield pf ICG guided LND and conventional LND is compared.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 8, 2019</start_date>
  <completion_date type="Anticipated">November 8, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 8, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective single arm study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Indocyanine green postive lymph node numbers</measure>
    <time_frame>15 day after surgery</time_frame>
    <description>total number of dissected lymph nodes which are indocyanine green positive</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total lymph node numbers of conventional extended lymph node dissection</measure>
    <time_frame>15 day after surgery</time_frame>
    <description>total number of dissected lymph nodes during conventional extended lymph node dissection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>pathology of indocyanine green positive lymph nodes</measure>
    <time_frame>15 day after surgery</time_frame>
    <description>İndocyanine green positvie lymph nodes are malign or benign</description>
  </primary_outcome>
  <primary_outcome>
    <measure>pathology of lymph nodes</measure>
    <time_frame>15 day after surgery</time_frame>
    <description>Pathology of material from conventional extended lymph node dissection</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Lymph Node Metastases</condition>
  <arm_group>
    <arm_group_label>ICG group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ICG injection before LRRP via cystoscopy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indocyanine green</intervention_name>
    <description>indocyanine green application during LRRP to detect positive lymph nodes. ICG will be injected to prostate lobes via csytoscopy</description>
    <arm_group_label>ICG group</arm_group_label>
    <other_name>Conventional ELND</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed locally limited prostate cancer;&#xD;
&#xD;
          -  Intermediate or high risk tumor&#xD;
&#xD;
          -  Recommended and planned prostatectomy;&#xD;
&#xD;
          -  Completed and signed written consent;&#xD;
&#xD;
          -  Voluntarily agreement to participate in this study&#xD;
&#xD;
          -  Age of the study participants ≥ 18 years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergic reaction to active ingredient (indocyanine green);&#xD;
&#xD;
          -  Iodine allergy;&#xD;
&#xD;
          -  Hyperthyroidism;&#xD;
&#xD;
          -  High-grade renal impairment;&#xD;
&#xD;
          -  High-grade hepatic insufficiency;&#xD;
&#xD;
          -  Unwillingness to the storage and disclosure of pseudonymous disease and personal data&#xD;
&#xD;
          -  psychiatric pre-existing conditions or other circumstances that make a cooperation by&#xD;
             the patient in question&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abdullah A Demirtaş, Md, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>TC Erciyes University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Abdullah A Demirtaş, MD, PRof</last_name>
    <phone>+905325094494</phone>
    <email>mesane@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Şevket TOLGA T Tombul, MD</last_name>
    <phone>05364774525</phone>
    <email>sevkettolgatombul@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Urology, Ercieys University, Faculty Of Medicine,</name>
      <address>
        <city>Kayseri</city>
        <zip>38039</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abdullah Demirtas, MD</last_name>
      <phone>+905325094494</phone>
      <email>mesane@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 31, 2021</study_first_submitted>
  <study_first_submitted_qc>May 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2021</study_first_posted>
  <last_update_submitted>May 8, 2021</last_update_submitted>
  <last_update_submitted_qc>May 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>TC Erciyes University</investigator_affiliation>
    <investigator_full_name>Abdullah Demirtas</investigator_full_name>
    <investigator_title>MD, Professor in Urology</investigator_title>
  </responsible_party>
  <keyword>indocyanine green based fluorescence imaging</keyword>
  <keyword>extendend lymph node dissection</keyword>
  <keyword>prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Lymphatic Metastasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

